Zollinger-Ellison Syndrome (Gastrinoma): A Comprehensive Guide

Overview

Zollinger-Ellison Syndrome (ZES) is a rare condition where one or more tumors, called gastrinomas, form in the pancreas or the upper part of the small intestine (duodenum). These tumors secrete large amounts of the hormone gastrin, which causes the stomach to produce too much acid. The excess acid leads to severe peptic ulcers, diarrhea, and other digestive symptoms.

Who it affects: ZES can occur at any age, but it is most commonly diagnosed in people between the ages of 30 and 60. It affects men slightly more often than women. While rare, ZES is estimated to occur in about 0.1 to 1% of people with peptic ulcers (NIH).

Prevalence: ZES is extremely uncommon, with an incidence of about 0.5 to 2 cases per million people per year (Cleveland Clinic). Approximately 25% of cases are associated with Multiple Endocrine Neoplasia Type 1 (MEN1), a genetic disorder that increases the risk of tumors in the endocrine system.

Symptoms

The symptoms of Zollinger-Ellison Syndrome are primarily caused by excess stomach acid and may include:

Common Symptoms

• Severe abdominal pain: Often described as burning or gnawing, typically in the upper abdomen. This pain may worsen at night or between meals.
• Diarrhea: Frequent, watery stools, which may be persistent and difficult to control. This occurs in up to 70% of patients (Mayo Clinic).
• Heartburn or acid reflux: A burning sensation in the chest, often worse after eating or lying down.
• Nausea and vomiting: May occur due to irritation of the stomach lining or ulcers.
• Weight loss: Unintentional weight loss can result from poor nutrient absorption due to diarrhea or reduced food intake because of pain.
• Loss of appetite: Some individuals may experience a decreased desire to eat due to persistent discomfort.

Less Common Symptoms

• Bleeding in the digestive tract: This can lead to black or tarry stools (melena) or vomiting blood (hematemesis), indicating a serious complication.
• Perforation of the stomach or intestine: Severe ulcers can create holes in the digestive tract, leading to severe pain and infection (peritonitis).
• Gastroesophageal reflux disease (GERD): Chronic acid reflux can damage the esophagus over time.
• Malabsorption: Difficulty absorbing nutrients, leading to deficiencies in vitamins and minerals.

Symptoms of ZES can mimic other digestive disorders, such as peptic ulcer disease, gastroesophageal reflux disease (GERD), or irritable bowel syndrome (IBS). This can make diagnosis challenging.

Causes and Risk Factors

Causes

Zollinger-Ellison Syndrome is caused by gastrin-secreting tumors (gastrinomas). These tumors are usually found in:

• The duodenum (first part of the small intestine) – about 70% of cases (NIH).
• The pancreas – about 25% of cases.
• Other locations, such as lymph nodes, stomach, or other organs (rare).

Gastrinomas can be benign (non-cancerous) or malignant (cancerous). About 60-90% of gastrinomas are malignant, meaning they can spread to other organs, such as the liver or nearby lymph nodes (Cleveland Clinic).

Risk Factors

While the exact cause of gastrinomas is unknown, certain factors may increase the risk of developing Zollinger-Ellison Syndrome:

• Multiple Endocrine Neoplasia Type 1 (MEN1): About 25% of people with ZES have MEN1, a genetic disorder that causes tumors in the endocrine glands (NIH). People with MEN1 often develop ZES at a younger age (before 40).
• Family history: A family history of MEN1 or other endocrine tumors may increase risk.
• Age and gender: ZES is more commonly diagnosed in men between 30 and 60 years old.

Most cases of ZES are sporadic, meaning they occur without a known genetic link or family history.

Diagnosis

Diagnosing Zollinger-Ellison Syndrome involves a combination of blood tests, imaging studies, and endoscopic procedures. Early diagnosis is crucial to prevent complications.

Diagnostic Tests

• Fasting gastrin blood test: This is the primary test for ZES. High levels of gastrin (typically greater than 1000 pg/mL) suggest the presence of a gastrinoma. However, other conditions (e.g., use of proton pump inhibitors, chronic kidney disease) can also elevate gastrin levels (Mayo Clinic).
• Secretin stimulation test: This test helps confirm ZES. Secretin (a hormone) is injected, and gastrin levels are measured. In people with ZES, gastrin levels rise significantly after secretin injection, whereas they do not in other conditions.
• Upper endoscopy: A flexible tube with a camera is used to examine the stomach and duodenum for ulcers or tumors.
• Imaging studies: These help locate tumors and determine if they have spread:
  • CT scan or MRI: Provides detailed images of the abdomen.
  • Somatostatin receptor scintigraphy (Octreoscan): A radioactive tracer is used to detect tumors that have somatostatin receptors (common in gastrinomas).
  • Endoscopic ultrasound (EUS): Combines endoscopy and ultrasound to locate small tumors in the pancreas or duodenum.
• Biopsy: If a tumor is found, a small tissue sample may be taken to confirm it is a gastrinoma.

Differential Diagnosis

ZES symptoms can overlap with other conditions, so doctors may also rule out:

• Peptic ulcer disease (not caused by ZES).
• Gastroesophageal reflux disease (GERD).
• Helicobacter pylori infection (a bacterial infection that causes ulcers).
• Chronic pancreatitis.
• Inflammatory bowel disease (e.g., Crohn’s disease).

Treatment Options

The goals of treatment for Zollinger-Ellison Syndrome are to:

• Reduce stomach acid production.
• Heal ulcers and prevent new ones.
• Manage or remove tumors.
• Prevent complications.

Medications

• Proton pump inhibitors (PPIs): These are the first-line treatment to reduce stomach acid. Examples include:
  • Omeprazole (Prilosec)
  • Lansoprazole (Prevacid)
  • Pantoprazole (Protonix)
  • Esomeprazole (Nexium)

  Patients with ZES often require higher doses of PPIs than those with typical acid reflux or ulcers.

• H2 blockers: These can also reduce stomach acid but are less effective than PPIs. Examples include:
  • Famotidine (Pepcid)
  • Ranitidine (Zantac, though recalled in some countries due to contaminants)
• Octreotide: A synthetic hormone that can reduce gastrin secretion in some cases, though it is not commonly used as a first-line treatment.

Surgical and Procedural Treatments

• Tumor removal (resection): If the tumor is localized and has not spread, surgery may be performed to remove it. This is more likely if the tumor is in the pancreas or duodenum and is benign.
• Liver-directed therapies: If the tumor has spread to the liver, treatments may include:
  • Liver resection (partial removal of the liver).
  • Radiofrequency ablation (using heat to destroy tumor cells).
  • Embolization (blocking blood flow to the tumor).
• Chemotherapy: Used if the tumor is malignant and has spread to other organs. Drugs like streptozocin, 5-fluorouracil (5-FU), or doxorubicin may be used.
• Peptide receptor radionuclide therapy (PRRT): A targeted radiation therapy for advanced gastrinomas that express somatostatin receptors.

Lifestyle and Dietary Changes

While medications are the primary treatment, certain lifestyle changes can help manage symptoms:

• Avoid trigger foods: Spicy foods, caffeine, alcohol, and fatty foods can worsen acid reflux and ulcers.
• Eat smaller, more frequent meals: This can help reduce stomach acid production and ease digestion.
• Quit smoking: Smoking increases stomach acid and can worsen ulcers.
• Manage stress: Stress can exacerbate symptoms, so techniques like meditation, yoga, or counseling may help.
• Stay hydrated: Diarrhea can lead to dehydration, so drinking plenty of fluids is important.

Living with Zollinger-Ellison Syndrome (Gastrinoma)

Living with ZES requires ongoing management, but many people with the condition lead active lives with proper treatment. Here are some tips for daily management:

Medication Adherence

• Take PPIs or other prescribed medications exactly as directed by your doctor. Do not stop or adjust doses without consulting them.
• Set reminders for medication times to ensure consistency.

Dietary Management

• Keep a food diary to identify and avoid foods that trigger symptoms.
• Work with a dietitian to create a low-acid, easy-to-digest meal plan.
• Consider supplements (e.g., vitamin B12, iron) if malabsorption is a concern, but only under medical supervision.

Regular Monitoring

• Attend all follow-up appointments with your gastroenterologist, endocrinologist, or oncologist.
• Undergo regular imaging tests (e.g., CT scans, MRIs) to monitor tumor growth or spread.
• Have periodic blood tests to check gastrin levels and overall health.

Emotional and Mental Health

• Join a support group for people with rare diseases or neuroendocrine tumors. Organizations like the Carcinoid Cancer Foundation or Neuroendocrine Tumor Research Foundation can provide resources.
• Seek counseling or therapy if you experience anxiety or depression related to your condition.

Travel and Emergency Preparedness

• Carry a list of your medications, dosages, and your doctor’s contact information.
• Pack extra medication when traveling in case of delays.
• Wear a medical alert bracelet indicating your condition, especially if you are at risk for severe complications.

Prevention

There is no known way to prevent Zollinger-Ellison Syndrome, as the exact cause of gastrinomas is unclear. However, the following steps may help reduce risk or detect the condition early:

Genetic Counseling

• If you have a family history of MEN1 or other endocrine tumors, consider genetic counseling and testing. Early detection of MEN1 can lead to earlier monitoring and intervention.

Regular Health Check-ups

• If you have a history of peptic ulcers or chronic diarrhea, discuss your symptoms with your doctor, especially if they are severe or recurrent.
• People with MEN1 should undergo regular screening for tumors, including gastrinomas.

Lifestyle Factors

• Avoid smoking and limit alcohol intake, as these can worsen stomach acid-related symptoms.
• Maintain a healthy diet and weight to support overall digestive health.

Complications

If left untreated, Zollinger-Ellison Syndrome can lead to serious, even life-threatening complications. These include:

Gastrointestinal Complications

• Severe ulcers: Ulcers can become deep and painful, affecting quality of life.
• Perforation: Ulcers can create holes in the stomach or intestinal wall, leading to peritonitis (a severe abdominal infection) or sepsis (a life-threatening response to infection).
• Bleeding: Ulcers can erode blood vessels, causing internal bleeding. Signs include vomiting blood (hematemesis) or black, tarry stools (melena).
• Obstruction: Scarring from ulcers can narrow the digestive tract, leading to blockages that require surgery.

Nutritional Complications

• Malabsorption: Chronic diarrhea and damage to the intestinal lining can lead to poor nutrient absorption, causing deficiencies in vitamins (e.g., B12, D) and minerals (e.g., iron, calcium).
• Weight loss and malnutrition: Persistent symptoms can lead to unintentional weight loss and weakness.

Tumor-Related Complications

• Metastasis: If the gastrinoma is malignant, it can spread to other organs, most commonly the liver, lymph nodes, or bones. This can lead to organ failure or other severe symptoms.
• Hormonal imbalances: In people with MEN1, other endocrine tumors can cause additional hormonal issues, such as hyperparathyroidism (overactive parathyroid glands).

Long-Term Medication Side Effects

• PPI side effects: Long-term use of proton pump inhibitors may increase the risk of:
  • Osteoporosis (weak bones).
  • Vitamin B12 deficiency.
  • Clostridium difficile infection (a bacterial infection causing severe diarrhea).
  • Kidney disease (in rare cases).

Regular monitoring and adherence to treatment can help prevent or manage these complications.

When to Seek Emergency Care

Sources and Further Reading

• Mayo Clinic. (2021). Zollinger-Ellison Syndrome.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2017). Zollinger-Ellison Syndrome.
• Cleveland Clinic. (2020). Zollinger-Ellison Syndrome (Gastrinoma).
• National Organization for Rare Disorders (NORD). (2020). Zollinger-Ellison Syndrome.
• Jensen, R. T., et al. (2016). "Gastrinomas: Advances in Diagnosis and Management." Neuroendocrinology, 103(1), 17–24.